Eckert & Ziegler SE is a provider of isotope technology for medical, scientific, and industrial applications. The company's core businesses comprise cancer therapy, industrial radiometry, and nuclear-medical imaging. It develops, manufactures, and distributes radiation sources, medical devices, and related components. Key subsidiaries include Eckert & Ziegler BEBIG GmbH, Isotope Products Laboratories (IPL) Inc., and IBt. The group serves customers in the healthcare, industrial, and scientific sectors globally, with operations in Europe, North America, and South America. Founded in 1997 as a holding company, the group traces its origins to the Zentralinstitut für Isotopentechnik. Notable acquisitions include the prostate cancer implants business of Biocompatibles Inc., the isotope specialist Nuclitec GmbH, and the radiopharmaceutical producer MC Pharma GmbH.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Medical Devices Homepage ezag.com
Sector Healthcare IR page ezag.com/investors
Tags
isotope technology, cancer therapy, brachytherapy, nuclear medicine, radiometry, radiopharmaceuticals, medical imaging, industrial radiation sources, radiochemistry, Eckert & Ziegler BEBIG GmbH, Isotope Products Laboratories (IPL) Inc., IBt, Nuclitec GmbH, MC Pharma GmbH, Tecnonuclear S.A., PENTIXAPHARM, Gamma-Service Group, BR-77 Comércio Distribuidora e Transportes de Medicamentos Ltda., BrachySolutions BVBA, OctreoPharm Sciences GmbH, Biocompatibles Inc., Mick Radio Nuclear Instruments Inc., Vitalea Science Inc., Bioscan Inc., Chemotrade Chemiehandelsgesellschaft mbH, EnergySolution’s UK sources and waste business, BSM Diagnostica Gesellschaft m.b.H., Cesio s.r.o, EUROTOPE Entwicklungsgesellschaft für Isotopentechnologien mbH, Isotope Products Europe Blaseg (IPE) GmbH, CIS bio International, DuPont Pharmaceuticals, North American Scientific, HEK GmbH, Analytics Atlanta Georgia (USA), REM Indústria e Comércio Ltda.
Press page —

Metrics

Valuation  
Market cap € 832.314M
Market cap (USD) $ 919.873M
P/E 72.30
PEG 3.90
P/BV 2.92
P/S 2.67
P/OCF 14.25
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 20.4%
ROI 19.2%
ROIC 29.1%
Profit margin 15.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 18.5%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 43.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 311.96M 295.85M 246.092M 222.26M 180.435M 176.139M 178.493M 168.709M 138.631M 137.935M 140.046M 127.256M 117.138M 119.997M 116.197M 111.093M 101.399M
Net profit 48.763M 33.276M 26.3M 29.278M 34.527M 17.954M 21.595M 16.133M 10.641M 9.729M 14.292M 8.257M 8.577M 8.681M 11.415M 10.415M 21.892M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price 15.26 44.5 41.3 46.4 94.1 44.84 190.6 95.3 — — 18.98 18.98 28.65 — — — —
Price performance 12m -0.66 0.08 -0.11 -0.51 1.1 -0.76 1 — — — 0 -0.34 — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Eckert & Ziegler Receives GMP Certificate for Actinium-225 Bull 5 Bear 0 Clinical/regulatory

Braunschweig, Germany, 28 October 2026. Eckert & Ziegler Therapeutics GmbH, wholly owned subsidiary of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Actinium-225 (Ac-225). The certification by the competent German authority confirms that production meets the stringent requirements of Good Manufacturing Practice (GMP) and facilitates the use of the radioisotope for the investigational treatment of patients.

Actinium-225 is widely regarded as one of the most promising alpha emitters for use in targeted radiopharmaceutical applications. This is reflected in both the increasing number of clinical trials investigating this radionuclide and the advancement of clinical programs into later-stage development.

“This regulatory milestone is the decisive step that turns our production capability into a supply commitment the field can build their clinical and commercial programs on,” said Dr. Gunnar Mann, Member of the Executive Board and responsible for Operations at Eckert & Ziegler’s Medical Segment. “We have quickly moved from first production runs in our upscaled process to GMP grade routine manufacturing. This is what improving supply security looks like in practice.”

The overall production route uses cyclotron-based irradiation of Radium-226 (Ra-226) at the Řež facilities of the Czech Academy of Sciences’ Nuclear Physics Institute (Ústav jaderné fyziky, “UJF”). Afterwards the irradiated material is processed at Eckert & Ziegler’s Braunschweig site to obtain GMP grade Ac-225. Production activities at both sites are supported by custom-engineered hot cell systems from Isotope Technologies Dresden GmbH, Eckert & Ziegler’s hot cell division.

The proprietary process set up by Eckert & Ziegler ensures that the cyclotron-based production of Ac-225 results in an isotopic profile with long-lived impurities such as Actinium-227 and Thorium-229 kept to a minimum, thereby meeting the expectations of nuclear medicine physicians and radiopharmacists alike.

Secured access to Radium-226
Accessing Ra-226 as the precursor material is one of the principal bottlenecks in global Ac-225 production. To alleviate the pressure on its supply chain, Eckert & Ziegler has integrated the repurposing of Ra-226 legacy sources into its sourcing strategy. Additionally, the production method recovers unconverted Ra-226 after irradiation and reintroduces it to the process, allowing the material to be used across multiple cycles. This helps reduce dependency on constrained global Ra-226 inventories while limiting radioactive waste, contributing to more predictable output volumes and costs for both radioisotope supply and CDMO programs.

Capacity expansion in Asia and North America
The newly opened production facility of Eckert & Ziegler’s joint venture Qi Kang Medical Technology (Changzhou) Co., Ltd. in Jintan, China is intended to become the first site in the country dedicated to the production of Ac-225 on a commercial scale. This second phase is planned to be realized after initial operations start in early 2027.
In addition, further capacity expansion can be considered at Eckert & Ziegler’s established radiopharmaceutical manufacturing site near Boston, MA, USA, as well as in Germany, to support the future commercial supply of Ac-225-based medicinal products.

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,100 employees, is THE leading independent radioisotope supplier and a specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
**Contributing to saving lives.

Prompts

Eckert & Ziegler SE (ticker EUZ), listed in Germany.

ETFs Holding Eckert & Ziegler SE

ETF Weight in ETF Shares Market value As of
DFIS 0.03% 97,272 $ 1.561M Nov 12, 2026
AVDS 0.02% 3,967 $ 67.193K Nov 16, 2026
AVDE 0.01% 65,360 $ 1.107M Nov 16, 2026
DFSI 0.01% 5,585 $ 89.619K Nov 12, 2026
DFIC 0.01% 66,407 $ 1.066M Nov 12, 2026
DFAI 0.00% 46,192 $ 741.215K Nov 12, 2026
DFAX 0.00% 26,332 $ 422.534K Nov 12, 2026